FDA Targets Obsolete Rules for 11 Disappeared Food Items
Published Date: 7/17/2025
Proposed Rule
Summary
The FDA is planning to cancel 11 food rules for products that aren’t sold anymore in the U.S. This change helps clear out old, unnecessary rules so businesses and consumers can enjoy a simpler food system. If this goes through, it won’t cost anyone extra and will make things easier for food makers and shoppers alike.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Revoking 11 Obsolete Food Standards
The FDA proposes to cancel 11 food standards for products that are no longer sold in the United States. If finalized, removing these obsolete rules may reduce unnecessary regulatory requirements for food makers, and the FDA says this action will not cost anyone extra.
Simpler Food System for Shoppers
The FDA proposes to revoke 11 food standards for items no longer sold in the U.S., which the agency says will help simplify the food system for businesses and shoppers. The FDA also states this change will not increase costs for consumers.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16728, Gastroenterology-Urology Devices; Reclassification of Diagnostic Endoscopic Light Source Systems To Be Renamed Cystoscopic Systems Intended as an Aid for Detection of Bladder Cancer
The Food and Drug Administration (FDA) is proposing to reclassify diagnostic endoscopic light source systems (product code OAY), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation with the name "Cystoscopic system intended as an aid for detection of bladder cancer," along with special controls that FDA believes are necessary to provide a reasonable assurance of the safety and effectiveness of these devices.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16727, Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
The Food and Drug Administration (FDA, the Agency, or we) is issuing a final order reclassifying in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes NYQ, MVD, OWE, and PNK), all postamendments class III (premarket approval) devices, into class II (special controls), subject to premarket notification. FDA is also establishing a new device classification regulation, along with the special controls that are necessary to provide a reasonable assurance of safety and effectiveness of this device type.
Previous / Next Documents
Previous: 2025-13420, Proposal To Revoke 23 Standards of Identity for Foods
The FDA wants to get rid of 23 old food rules that aren’t really needed anymore to keep things honest for shoppers. This change will make life easier for food makers by cutting down on extra paperwork. If approved, these updates could save time and money without hurting what’s in your food.
Next: 2025-13424, Proposal To Revoke 18 Standards of Identity for Dairy Products
The FDA wants to get rid of 18 old rules that define what certain dairy products must be. This change will make things simpler for dairy makers and won’t hurt consumers. If approved, the new rules could save time and money by cutting unnecessary red tape.